Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Overview of Castleman disease

Angela Dispenzieri, David C. Fajgenbaum

Blood (2020) 135 (16): 1353–1364.

https://doi.org/10.1182/blood.2019000931

Published: 2020

Journal Articles

A Meta-Analysis of Genetic Abnormalities and Next Generation Sequencing of Primary Cases of Castleman Disease

Alexandra Butzmann, MD, Joanna Przybyl, PhD, Kaushik Sridhar, MS, Jyoti Kumar, MDMS, Nivaz Brar, BS, James L Zehnder, Roger A Warnke, MD, Robert S. Ohgami, MD PhD

Blood (2019) 134 (Supplement_1): 5227.

https://doi.org/10.1182/blood-2019-131261

Published: 2019

Journal Articles

Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients

Anna Wing, Wenzhao Meng, PhD, Gerald Wertheim, MD, PhD, Dale Frank, MD, Michele Paessler, D.O., Megan S. Lim, MD, PhD, Eline T. Luning Prak, MD, PhD, David C Fajgenbaum, MD MBA, MSc, Vinodh Pillai, MD, PhD

Blood (2018) 132 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2018-99-116487

Published: 2018

Journal Articles

Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization

Meera Mohan, MD, James C Meek, MD, Mary Elizabeth Meek, MD, Ralph Lynn Broadwater, MD, Katie Stone, BS, Amy Greenway, Daisy Alapat, MD, Frits van Rhee, MD PhD

Blood (2018) 132 (Supplement 1): 2415.

https://doi.org/10.1182/blood-2018-99-119820

Published: 2018

Journal Articles

Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome

Dustin Shilling, PhD, Dale M Kobrin, BA, David C Fajgenbaum, MD MBA, MSc

Blood (2018) 132 (Supplement 1): 1121.

https://doi.org/10.1182/blood-2018-99-118434

Published: 2018

Journal Articles

Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses

Christopher Sheild Nabel, MD PhD, Stephen Sameroff, BS, Dustin Shilling, PhD, Jason R Ruth, PhD, Mitsuhiro Kawano, MD, Yasuharu Sato, MD, Noriko Iwaki, MD, Federico Valdivieso, BS, Michael Feldman, MD, Katie Stone, BS, Daisy Alapat, MD, Frits van Rhee, MD PhD, Amy Chadburn, MD, Signe Spetalen, MD, Alexander Fosså, MD PhD, W. Ian Lipkin, MD, David C Fajgenbaum, MDMBA,MSc

Blood (2017) 130 (Supplement 1): 3589.

https://doi.org/10.1182/blood.V130.Suppl_1.3589.3589

Published: 2017

Journal Articles

Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease

David C Fajgenbaum, MDMBA,MSc, Sheila K Pierson, MS, Dustin Shilling, PhD, Cooper Gardner, Amy Y Liu, BS, Jasira Ziglar, BS, Shawnee Bernstein, BS, Sarah Mann, BS, Jeremy Zuckerberg, MD, Martin Lukac, MD PhD MPH, Raj Kuhan Jayanthan, MD, Mary Guilfoyle, MS, Craig Tendler, MD, Jason R Ruth, PhD, Thomas S Uldrick, MDMS, Frits van Rhee, MD PhD

Blood (2017) 130 (Supplement 1): 4647.

https://doi.org/10.1182/blood.V130.Suppl_1.4647.4647

Published: 2017

Journal Articles

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Li Yu, Meifeng Tu, Jorge Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, Sattva Neelapu, Prajwal C. Boddu, Mary A. Akosile, Thomas S. Uldrick, Robert Yarchoan, L. Jeffrey Medeiros, Yong Li, David C. Fajgenbaum, Ken H. Young

Blood (2017) 129 (12): 1658–1668.

https://doi.org/10.1182/blood-2016-11-748855

Published: 2017

Journal Articles

Human Immunodeficiency Virus-Negative Castleman's Disease: Clinicopathological and Laboratory Characteristics and Outcomes in Patients Treated in a Single Institution

Nalini Hasija, MD, Liliana Bustamante, MD, Michael V. Jaglal, MD, Lubomir Sokol, MD PhD

Blood (2015) 126 (23): 5027.

https://doi.org/10.1182/blood.V126.23.5027.5027

Published: 2015

Journal Articles

Development and Preliminary Usability and Accuracy Testing of the EBMT Gvhd App to Support Graft Versus Host Disease Diagnosis and Scoring According to NIH Criteria, By the EBMT Complications and Quality of Life Working Party

Schoemans Helene, Kathy Goris, Raf Van Durm, Jasper Van Hoof, Hildegard T. Greinix, MD, Daniel Wolff, Steven Z. Pavletic, MD, Stephanie J. Lee, MD MPH, Johan Maertens, MD PhD, Sabina De Geest, PhDRN, Fabienne Dobbels, Rafael F. Duarte, MD PhD

Blood (2015) 126 (23): 3151.

https://doi.org/10.1182/blood.V126.23.3151.3151

Published: 2015

Journal Articles

Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts

Mahmoud Elsawy, MD MSc, Barry E. Storer, PhD, Brenda M. Sandmaier, MD, Colleen Delaney, MD MSC, Frederick R. Appelbaum, MD, Ann E Woolfrey, MD, David G Maloney, MDPhD, Rainer F. Storb, MD, Mohamed L. Sorror, MD MSc

Blood (2014) 124 (21): 2583.

https://doi.org/10.1182/blood.V124.21.2583.2583

Published: 2014

Journal Articles

Charlson Comorbidity Index (CCI) and Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Do Not Predict Transplant Related Mortality (TRM) and Post-Transplant Outcomes In Young Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation

Oana V. Paun, MD, Tamila L. Kindwall-Keller, DO, Hillard M. Lazarus, MD, Mary J. Laughlin, MD, Paolo F. Caimi, MD, Merle J. Kolk, Richard J. Creger, Pharm D, Huda Salman, MD, Stanton L. Gerson, MD, Brenda W Cooper, MD

Blood (2013) 122 (21): 4582.

https://doi.org/10.1182/blood.V122.21.4582.4582

Published: 2013

Journal Articles

Use of a Claims Database to Characterize and Estimate the Incidence of Castleman's Disease

Maneesha Mehra, M.SC, MPH, Nicole Cossrow, MPH, PhD, Robert A Stellhorn, MS, Jessica Vermeulen, MD, PhD, Avinash Desai, MD, Nikhil C. Munshi, MD

Blood (2012) 120 (21): 4253.

https://doi.org/10.1182/blood.V120.21.4253.4253

Published: 2012

Journal Articles

What Is the Role of Red Blood Cell Transfusion Threshold on Number of Transfusions in Pediatric Patients After Hematopoietic Stem Cell Transplant?

Rachel S. Bercovitz, M.D., Andrew C. Dietz, M.D., M.S., Rhamy N. Magid, M.D., Nicole D. Zantek, M.D., Ph.D., Angela R. Smith, MD, MS, Ralph R. Quinones, M.D.

Blood (2011) 118 (21): 1263.

https://doi.org/10.1182/blood.V118.21.1263.1263

Published: 2011

Journal Articles

Castleman's Disease's Clinical Course and Management: A Study of 20 Cases

Jijun Liu, MD, Lori C. Kim, MD, Jianguo Tao, MD, PhD, Lubomir Sokol, MD, PhD

Blood (2010) 116 (21): 5091.

https://doi.org/10.1182/blood.V116.21.5091.5091

Published: 2010

Journal Articles

Anti-IL6 Antibody (ab) Based Strategies Improve the Management of HIV Negative Castleman’s Disease.

Frits van Rhee, MD, PhD, Mir Alikhan, MD, Nikhil Munshi, MD, PhD, Ron Walker, MD, James Waldron, MD, Guido Tricot, MD, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 3283.

https://doi.org/10.1182/blood.V104.11.3283.3283

Published: 2004

NARROW

Overview of Castleman disease

A Meta-Analysis of Genetic Abnormalities and Next Generation Sequencing of Primary Cases of Castleman Disease

Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients

Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization

Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome

Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses

Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Human Immunodeficiency Virus-Negative Castleman's Disease: Clinicopathological and Laboratory Characteristics and Outcomes in Patients Treated in a Single Institution

Development and Preliminary Usability and Accuracy Testing of the EBMT Gvhd App to Support Graft Versus Host Disease Diagnosis and Scoring According to NIH Criteria, By the EBMT Complications and Quality of Life Working Party

Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts

Charlson Comorbidity Index (CCI) and Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Do Not Predict Transplant Related Mortality (TRM) and Post-Transplant Outcomes In Young Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation

Use of a Claims Database to Characterize and Estimate the Incidence of Castleman's Disease

What Is the Role of Red Blood Cell Transfusion Threshold on Number of Transfusions in Pediatric Patients After Hematopoietic Stem Cell Transplant?

Castleman's Disease's Clinical Course and Management: A Study of 20 Cases

Anti-IL6 Antibody (ab) Based Strategies Improve the Management of HIV Negative Castleman’s Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only